The drug price of Plessitinib is currently around $60,000 in China, and may vary slightly from region to region. Plessitinib is a RET inhibitor, currently approved indications include advanced RET gene fusion mutation-positive non-small cell lung cancer, advanced medullary thyroid cancer with RET gene mutation over 12 years old, advanced refractory RET gene fusion mutation thyroid cancer. The current market price is about 60,000 RMB, and the specific price is affected by many factors such as region and hospital. Plessitinib use may produce lung damage, liver function damage, bleeding, hypertension, leukopenia, thrombocytopenia and many other side effects, allergic to the drug is prohibited, with severe high blood pressure, severe liver function damage, use with caution. The drug must be used under the guidance of a professional doctor, do not blindly use and stop using the drug, if any discomfort during the use of the drug timely consultation, so as to avoid delays in treatment.